Alpha Tau Reports Strong Pancreatic Cancer Survival Data at ASCO, Exceeding Historical Outcomes
DRTS has more than doubled off its 52-week low of $2.81 on elevated volume (2.7× avg).
Summary
Alpha Tau Medical reported strong overall survival and safety data for its Alpha DaRT pancreatic cancer therapy at the ASCO Annual Meeting, demonstrating significant improvements over historical outcomes for patients with limited treatment options.
Key Events · Product Development and Regulatory · DRTS
-
Strong Overall Survival Results
A pooled analysis of three Phase I/II studies demonstrated encouraging median overall survival (mOS) for Alpha DaRT in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients.
-
Significant Efficacy vs. Historical Data
Alpha DaRT as second-line therapy achieved mOS of 11.2 months (metastatic) and 11.1 months (locally advanced) from enrollment, significantly exceeding historical ~4-9 months. As third-line therapy, it achieved mOS of 7.9-8.8 months, compared to historical ~4-7 months.
-
Favorable Safety Profile
The therapy showed a favorable safety profile with treatment-associated adverse events in 36% of subjects and Grade ≥3 events in 9% (all resolved), with no treatment-related deaths or chronic toxicity.
-
Presented at ASCO Annual Meeting
These positive results were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, a major medical conference, adding significant validation and visibility.
Analysis · DRTS · Industrial Applications And Services
Alpha Tau Medical announced highly encouraging overall survival and safety results from its Alpha DaRT therapy in pancreatic cancer, presented at the ASCO Annual Meeting. The data showed significantly extended median overall survival for patients, particularly in second and third-line settings, compared to historical benchmarks, alongside a favorable safety profile. This positive clinical update for a highly lethal cancer significantly de-risks the therapy and strengthens the company's development pipeline.
At the time of this filing, DRTS was trading at $10.94 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $953.1M. The 52-week trading range was $2.81 to $11.62. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.